Hi an, - The success of secondary radiation as a potential "cure" for Prostate Cancer (PCa) following "failed" surgery, is largely dependent on whether the source of the recurrence as demonstrated by an "elevated" post-surgical PSA blood test (>0.1 or 0.2 ng/ml), is "localized" or "systemic" in origin.
Unfortunately, this is seldom easily determined and therefor, most often, a subjective judgment has to be made, based on a variety of diagnostic information that should be available. These include, but are not limited to, age, the PSA at the time of treatment and now, time from treatment to the recurrence, did the monitoring PSA results ever reach traditional, clinically "undetectable" levels (<0.1 ng/ml) and the findings contained in the post-surgical Pathology Report such as Gleason Score, and extent of disease/location.
Systemic disease refers to malignant cells that have escaped the Prostate and invaded the blood/lymph systems and are circulating within the body or haven taken root elsewhere, in the form of distant metastases. If such cells exist at a size and/or Stage that is unable to be detected with todays technology they are often referred to as "micro" cells or metastases.
The potential for their existence increases in direct proportion to the "favorable" or "unfavorable" levels of the items mentioned above. When determining the likelihood of "localized" disease, which is the only kind curatively effective by any treatment but Hormone Therapy (HT) and/or Chemo, earlier recurrence is less favorable than more prolonged time-frames. As a group, patients with less favorable (over-all) positive margins, actually have better statistical success rates with Salvage Radiation Therapy (SRT) than do those with more desirable (over-all) negative surgical margins.
But the effects on decision making should be the conclusions reached by weighing ALL of the diagnostic "clues" involved and the potential risk/reward ratio that they imply. So what do you do if it can't be determined, WITH CERTAINTY, whether the recurrence is localized or not?
You then weigh your POSSIBILITY for a potential "cure" based upon the above, versus the reality of (widely varying, but sometimes prolonged) remission control offered by HT against their potential for increased morbidity (side effects).
These are not easy decisions and professional guidance can help sort through the considerations and options, but it comes down to the fact that secondary treatment for, hopefully, localized disease is presently your last chance for "cure" as opposed to efforts to control a chronic disease. Its potential for success, in your INDIVIDUAL situation should be the determining factor, since statistical results are determined by data from large groups of men and cannot be directly transferred to INDIVIDUAL patients.
Good luck! - John@newPCa.org (aka) az4peaks